Carolina Constantin

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

Michael Untch, Richard D. Gelber, Christian Jackisch et al. · Annals of Oncology · 2008 · 196 citations

Oncology, Hera Trial, Clinical Evidence +5

Critical assessment and integration of separate lines of evidence for risk assessment of chemical mixtures

Antonio F. Hernández, Aleksandra Buha Djordjević, Carolina Constantin et al. · Archives of Toxicology · 2019 · 94 citations · Full text

Genotoxic, cytotoxic, and cytopathological effects in rats exposed for 18 months to a mixture of 13 chemicals in doses below NOAEL levels

Aristidis Tsatsakis, Anca Oana Docea, Carolina Constantin et al. · Toxicology Letters · 2019 · 82 citations

Cytopathological Effects, Medicine, Noael Levels +7

Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors

Sabina Zurac, Monica Neagu, Carolina Constantin et al. · Oncology Letters · 2016 · 69 citations · Full text

Perineural Invasion, Medicine, Melanoma Regression Spectrum +14

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

Axel Grothey, Kim Jordan, O Kellner et al. · European Journal of Cancer Supplements · 2003 · 63 citations

First-line Therapy, Oncology, Gastrointestinal Oncology +10